# Labeled NSAID hypersensitivity and the risk of opioid prescribing; an observational study

**Authors:** Laila Carolina Abu Esba, Reham Alhoraibi, Salem Abu Al-Burak, Husam I. Ardah

PMC · DOI: 10.3389/falgy.2025.1611309 · Frontiers in Allergy · 2025-07-29

## TL;DR

This study finds that people with NSAID allergies are more likely to be prescribed opioids, but many could safely use other NSAIDs if properly assessed.

## Contribution

The study provides evidence linking NSAID hypersensitivity misclassification to increased opioid use and highlights the underuse of COX-2 inhibitors as alternatives.

## Key findings

- Patients with NSAID hypersensitivity were 62% more likely to receive opioids compared to those with penicillin hypersensitivity.
- Only 10% of NSAID hypersensitive patients were prescribed COX-2 selective inhibitors like celecoxib.
- Many hypersensitive patients tolerated alternative NSAIDs despite concerns about cross-reactivity.

## Abstract

NSAIDs are widely used for pain management but are second only to antibiotics in causing drug hypersensitivity reactions. Misclassification of these reactions often leads to unnecessary avoidance of the entire drug class, potentially resulting in increased opioid prescribing. This study aimed to assess the prevalence and characteristics of NSAID hypersensitivity, cross-reactivity patterns, and the association between NSAID hypersensitivity and opioid prescribing. The use of COX-2 selective inhibitors as a safe alternative was also explored.

A retrospective cohort study was conducted at a tertiary care hospital, including patients with documented NSAID hypersensitivity between 2016 and 2023. Data on demographics, hypersensitivity reactions, NSAID cross-reactivity, and opioid prescriptions were collected. Patients with penicillin hypersensitivity were included for comparison. Logistic regression was used to analyze the association between NSAID hypersensitivity and opioid prescribing.

Among 319 patients with NSAID hypersensitivity, 30% (n = 96) were classified as true allergy, 12.5% (n = 40) as pseudo-allergy, and 57% (n = 183) were unclassified. Cross-reactivity between NSAIDs was observed in 13%, although 52% tolerated at least one other NSAID. Patients with NSAID hypersensitivity were 62% more likely to be prescribed opioids compared to those with penicillin hypersensitivity [adjusted OR 1.62 (95% CI: 1.40–1.88), p < 0.001]. Celecoxib was underutilized, prescribed to only 10% of hypersensitive patients.

NSAID hypersensitivity is associated with increased opioid prescribing due to class-wide avoidance. Despite concerns about cross-reactivity, many patients can tolerate alternative NSAIDs. Improved classification tools and clinical decision support systems are needed to guide prescribers.

## Linked entities

- **Chemicals:** Celecoxib (PubChem CID 2662)
- **Diseases:** pseudo-allergy (MONDO:0044981)

## Full-text entities

- **Genes:** COX2 (cytochrome c oxidase subunit II) [NCBI Gene 4513] {aka COII, MTCO2}
- **Diseases:** pain (MESH:D010146), NSAID hypersensitivity (MESH:D004342)
- **Chemicals:** Celecoxib (MESH:D000068579)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12339446/full.md

## References

28 references — full list in the complete paper: https://tomesphere.com/paper/PMC12339446/full.md

---
Source: https://tomesphere.com/paper/PMC12339446